Sign In
Buy LIFE
$16.89
-0.375 (-2.17%)
At Close: Jun 03, 2026
Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect?
11:17am, Wednesday, 06'th Apr 2022
The consensus price target hints at a 235.8% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
12:00pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
08:00am, Friday, 01'st Apr 2022
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological p
Can Atyr Pharma (LIFE) Climb 266% to Reach the Level Wall Street Analysts Expect?
02:00pm, Monday, 21'st Mar 2022 Zacks Investment Research
The consensus price target hints at a 265.6% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
04:00pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
01:32pm, Thursday, 17'th Mar 2022
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
aTyr Pharma files for $200M mixed shelf offering
09:56pm, Tuesday, 15'th Mar 2022 Seeking Alpha
aTyr Pharma (LIFE) has filed for a $200M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.The company said it will use…
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript
03:02am, Tuesday, 15'th Mar 2022 Seeking AlphaaTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript
11:02pm, Monday, 14'th Mar 2022
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
08:00pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022.
Avetta Launches Supply Chain Sustainability and ESG Risk Mitigation Solution on Avetta One Platform
10:31pm, Sunday, 13'th Mar 2022 Kwhen Finance
aTyr Pharma Q4 2021 Earnings Preview
10:35pm, Friday, 11'th Mar 2022 Seeking Alpha
aTyr Pharma (NASDAQ:LIFE) is scheduled to announce Q4 earnings results on Monday, March 14th, after market close.The consensus EPS Estimate is -$0.28 (+40.4% Y/Y) and the consensus…
LIFE stock rises on plans to begin registrational trial for lead asset (NASDAQ:LIFE)
04:07pm, Thursday, 10'th Mar 2022 Seeking Alpha
After a meeting with the U.S. Food and Drug Administration ((FDA)), the clinical-stage biotech aTyr Pharma (LIFE) announced on Thursday that the company expected to initiate…
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
01:03pm, Thursday, 10'th Mar 2022 GlobeNewswire Inc.
Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022. Regulatory path forward supports company’s intention to initiate a pla
